GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme…
GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the…
Read More...
Read More...
